Nextperm, which is developing a vegan protein substitute, has announced that it has reached a third milestone it has set for itself in 2021: a commercial production agreement for its flagship product ProteVin, with GFR Canadian Ingredients. GFR manufactures vegan nutrients for the food market. The agreement grants GFR a license to produce the protein only and does not include the transfer of intellectual property rights. ProteVin is a genetically engineered non-GMO vegan protein substitute based on yeast. The agreement will allow the production of ProteVin with a commercial volume of tens of tons in 2022, a quantity that will allow the company to begin commercial launch of the product in the US in the first half of 2022. So far the company has received two commercial orders from American companies for ProteVin product.
Comments
Thanks!
Your response was successfully received , and will be published according to the system policy
Your response was successfully received , and will be published according to the system policy
You can receive an email notification when your response is approved and published.
Thanks!
Your response has been successfully received, and will be published according to the system policy
An error occurred while submitting the response
Please try again later
Please try again later
Sort out The responses Arrange the responses
Main Articles on the Site
Note: This article has been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here (adsbygoogle=window.adsbygoogle || ).push();